Results 251 to 260 of about 946,861 (341)

Propensity Matched Analysis of 14 French Suture‐ Versus Plug‐Based Vascular Closure During Transfemoral Transcatheter Aortic Valve Replacement (TAVR)

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Plug‐based vascular closure devices (Pb‐VCD) and suture‐based vascular closure devices (Sb‐VCD) are used for percutaneous vascular access site closure during transcatheter aortic valve replacement (TAVR). Until now, no clear superiority of either device was shown in studies comparing 18 F VCDs solely.
Tobias Lerchner   +6 more
wiley   +1 more source

Spotlight commentary: Using real‐world data for real‐world evidence generation to advance drug repurposing

open access: yes
British Journal of Clinical Pharmacology, EarlyView.
George S. Q. Tan, Jenni Ilomäki
wiley   +1 more source

Microtracer‐Based Assessment of the Mass Balance, Pharmacokinetics, and Excretion of [14C]Berzosertib, an Intravenous ATR Inhibitor, in Patients With Advanced Solid Tumors: A Phase 1 Study

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Berzosertib is a small‐molecule ataxia telangiectasia and Rad3‐related protein inhibitor. To assess the clearance mechanism(s) of berzosertib, a Phase 1, 2‐period, open‐label study was conducted in adults with advanced solid tumors who were treated with a single intravenous dose of 210 mg/m2 berzosertib containing approximately 3 µCi of [14C ...
Jayaprakasam Bolleddula   +12 more
wiley   +1 more source

THE LIPID AND MINERAL DISTRIBUTION OF THE SERUM AND ERYTHROCYTES IN THE HEMOLYTIC AND HYPOCHROMIC ANEMIAS OF CHILDHOOD

open access: hybrid, 1937
Betty Nims Erickson   +4 more
openalex   +1 more source

Use of PopPK and E‐R Analyses toward Explaining Causal Link Between ADAMTS13 in Recombinant vs. Plasma‐Based Therapies and Clinical Effects in cTTP

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra‐rare, potentially life‐threatening condition caused by a deficiency of the blood enzyme ADAMTS13. Until now, ADAMTS13 replacement has been achieved with infusions of plasma or plasma‐based therapies (PBT).
Munjal Patel   +11 more
wiley   +1 more source

Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal Impairment

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pemetrexed is a cornerstone in chemo(immunotherapy) of non‐small cell lung cancer and mesothelioma; however, it is contraindicated in patients with renal impairment due to severe toxicity concerns. Therefore, a large proportion of patients is withheld from effective chemo(immunotherapy).
Nikki de Rouw   +18 more
wiley   +1 more source

Analysis of red blood cell lifespan and associated influencing factors in anemic dialysis patients. [PDF]

open access: yesRen Fail
Wu J   +13 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy